Cargando…

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

Oncogenic mutation of the RET receptor tyrosine kinase is observed in several human malignancies. Here, we describe three novel type II RET tyrosine kinase inhibitors (TKI), ALW-II-41-27, XMD15-44 and HG-6-63-01, that inhibit the cellular activity of oncogenic RET mutants at two digit nanomolar conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moccia, Marialuisa, Liu, Qingsong, Guida, Teresa, Federico, Giorgia, Brescia, Annalisa, Zhao, Zheng, Choi, Hwan Geun, Deng, Xianming, Tan, Li, Wang, Jinhua, Billaud, Marc, Gray, Nathanael S., Carlomagno, Francesca, Santoro, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457528/ https://www.ncbi.nlm.nih.gov/pubmed/26046350 http://dx.doi.org/10.1371/journal.pone.0128364

Ejemplares similares

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Moccia, Marialuisa, et al.
Publicado: (2021)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
por: Moccia, Marialuisa, et al.
Publicado: (2020)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

c-RET Molecule in Malignant Melanoma from Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines
por: Ohshima, Yuichiro, et al.
Publicado: (2010)

DNA Topoisomerases Participate in Fragility of the Oncogene RET
por: Dillon, Laura W., et al.
Publicado: (2013)

Alterations of RET, Oncogene in Human Adrenal Tumors
por: Lin, Shiu‐Ru, et al.
Publicado: (1998)

Expression of ret Proto‐oncogene in Human Neuroblastomas
por: Nagao, Minako, et al.
Publicado: (1990)

Roles of the RET Proto-oncogene in Cancer and Development
por: Takahashi, Masahide, et al.
Publicado: (2020)

Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.
por: Fabien, N., et al.
Publicado: (1992)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

Hair graying with aging in mice carrying oncogenic RET
por: Iida, Machiko, et al.
Publicado: (2020)

Distribution of RET proto‐oncogene variants in children with appendicitis
por: Schultz, Jurek, et al.
Publicado: (2022)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency
por: Pecce, Valeria, et al.
Publicado: (2018)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
por: Kucharczyk, Tomasz, et al.
Publicado: (2022)

THE RET/PTC-3 ONCOGENE ACTIVATES CLASSICAL NF-κB BY STABILIZING NIK
por: Neely, Robert J., et al.
Publicado: (2010)

PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential
por: Yadav, Leena, et al.
Publicado: (2020)

Precision oncology for RET-related tumors
por: Verrienti, Antonella, et al.
Publicado: (2022)

Multiple endocrine neoplasias type 2B and RET proto-oncogene
por: Martucciello, Giuseppe, et al.
Publicado: (2012)

Predicting Phenotypic Severity of Uncertain Gene Variants in the RET Proto-Oncogene
por: Crockett, David K., et al.
Publicado: (2011)

MON-392 Bilateral Pheocromocytoma With A Ret Proto-oncogene Mutation
por: López Maldonado, Francisco, et al.
Publicado: (2019)

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer
por: Guan, Luyao, et al.
Publicado: (2020)

Surgical Remission of Diabetes in a Patient With Mutation of RET Proto-Oncogene
por: Concepción Zavaleta, Marcio José, et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans
por: Plaza-Menacho, Iván, et al.
Publicado: (2014)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

A Study on Genetic Polymorphism of RET Proto-Oncogene in Hirschsprung's Disease in Children
por: Kumari, Madhu, et al.
Publicado: (2020)

Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics
por: Parate, Shraddha, et al.
Publicado: (2022)

Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence
por: Tong, Xiaotian, et al.
Publicado: (2011)

Bilateral adrenal pheochromocytoma with a germline L790F mutation in the RET oncogene
por: Min, Jun Won, et al.
Publicado: (2012)

Low Frequency of Rearrangements of the ret and trk Proto‐oncogenes in Japanese Thyroid Papillary Carcinomas
por: Wajjwalku, Worawidh, et al.
Publicado: (1992)

Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations
por: Ali, Hafiz Muhammad, et al.
Publicado: (2014)

DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells
por: Gandhi, Manoj, et al.
Publicado: (2010)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

MON-450 Prophylactic Thyroidectomy in a Patient with Codon 891 Mutation of the RET Proto-Oncogene
por: Swami, Janya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r1gaupr7mvmdlbr3vqq717bnao